Boehringer Ingelheim (BI) and Click Therapeutics collaboration Develop and commercialize a second prescription-based digital therapy (PDT) that provides additional treatment options for people with schizophrenia.
This new mobile application combines multiple clinically validated therapeutic interventions, used alone or in combination with pharmacotherapy, to help people with schizophrenia achieve positive clinical outcomes. make it achievable. Due to the current lack of access to psychosocial interventions, there remains a significant unmet need.
schizophrenia is one of the 15 leading causes of disability worldwide. Approximately half of all patients present with concurrent psychiatric and/or behavioral disturbances. Serious mental health conditions change a person’s perception of reality and affect how they think, feel and act.
Due to inadequate treatment of negative symptoms such as cognitive impairment and limited social functioning, those diagnosed may remain functionally impaired.
Treatment guidelines for schizophrenia recommend individualized psychosocial intervention therapy. However, access to such interventions is limited. It is therefore proposed that providing new digital treatment options could significantly improve treatment and patient health and quality of life.
of Expanding collaboration The collaboration between Boehringer Ingelheim and Click Therapeutics builds on the clinical success and important patient insights gained under the existing collaboration effective from September 2020. Future registry study.
Click Therapeutics will receive upfront payments, funding for research and development activities, plus clinical, regulatory and commercial milestone payments totaling up to $460 million and tiered royalties.
Nedim Pipic, PhD, is Corporate Vice President and Head of Therapeutic Areas for CNS, Retinopathy and Emerging Areas. Boehringer Ingelheim, said: Combining pharmacotherapy with emerging digital technologies opens up new horizons in our journey towards advancing mental health care. “
Cornelia Dorner-Ciossek, PhD, Digital Health Lead BI“This new project addresses a patient condition for which no scalable therapeutic approach currently exists. Seeing the PDT pipeline grow is a reflection of our commitment to mental health.” I have.”
Austin Speier, Chief Strategy Officer at Click Therapeutics also commented:Outcomes for people living together schizophrenia“
of original collaboration The contract for CT-155 was $500 million.
